Relmada Therapeutics Inc (RLMD) Director Paul Edward Kelly Buys 100,000 Shares

Share on StockTwits

Relmada Therapeutics Inc (OTCMKTS:RLMD) Director Paul Edward Kelly acquired 100,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $150,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Relmada Therapeutics stock traded up $0.02 during trading hours on Wednesday, reaching $1.83. The company’s stock had a trading volume of 13,848 shares, compared to its average volume of 20,422. Relmada Therapeutics Inc has a one year low of $0.80 and a one year high of $2.01.

Separately, ValuEngine raised shares of Relmada Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2019/05/15/relmada-therapeutics-inc-rlmd-director-paul-edward-kelly-buys-100000-shares.html.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.

Featured Story: What is a Stop Order?

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.